PF-07853578 free base · Synonyms: PNPLA3 degrader-1 | PNPLA3-148M degrader

PF-07853578 (Example 11) is a PNPLA3 degrader with an EC50 of 8 nM.

For research use only. Not for human or veterinary use.

Target PNPLA3

Research area Metabolic Disease Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

PF-07853578 structure

CAS No.: 3036158-98-9

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
5 mg	USD 498.00	BP-00756-5mg	In stock	Get quote
10 mg	USD 798.00	BP-00756-10mg	In stock	Get quote
25 mg	USD 1,598.00	BP-00756-25mg	In stock	Get quote
50 mg	USD 2,298.00	BP-00756-50mg	In stock	Get quote
100 mg	Inquire	BP-00756-100mg	In stock	Inquire
250 mg	Inquire	BP-00756-250mg	In stock	Inquire

Need another size or custom synthesis? Request a quote.

Description

PF-07853578 (Example 11) is a PNPLA3 degrader with an EC50 of 8 nM. PNPLA3 degrader-1 can be used in the study of cirrhosis and hepatocellular carcinoma.

Biological activity

In Vitro PF-07853578 (Example 11) exhibits EC50 values of 5 nM (lipid droplet localization assay) and 8 nM (Western blot assay) against hPNPLA3-I148M in human hepatocytes. In Vivo PF-07853578 (30 mg/kg; diet administration; 14 days) reduces PNPLA3 protein levels and decreases hepatic triglyceride accumulation in BAC-TG transgenic mice fed a high-sucrose diet.

Identifiers

SMILES: C[C@@H]1CCN([C@H]2CN(CC(F)(F)C2)C(=O)OC2=CC=C(Cl)C=C2)S1(=O)=O
InChIKey: LWZQGRRGKYWBQG-DGCLKSJQSA-N

Specifications

MW (average): 408.8480
Formula: C₁₆H₁₉ClF₂N₂O₄S
CAS No.: 3036158-98-9
Physical state: Solid
Color: white to off-white
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder 4℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO

In vitro: DMSO : 100 mg/mL

Documents

References

[1]. Justin Dran BOYD, et al. Use of patatin-like phospholipase domain-containing protein 3 compounds. WO2024084363A1. 2024-04-25.

[2]. Lindén D, et al. Targeting PNPLA3 to Treat MASH and MASH Related Fibrosis and Cirrhosis. Liver Int. 2025;45(4):e16186.

Same research area

Search Metabolic Disease